Contents

1. Landmarks in Tuberculosis Treatment **1**

2. Case Definitions in Tuberculosis **8**

- Case Definitions 8
- Disease Classification 9
- Types of Tuberculosis Patients 11
- Directly Observed Treatment 11
- Directly Observed Treatment Plus 12
- Treatment Outcomes of DOTS 12
- Drug Resistant Tuberculosis 13
- Treatment Outcomes in DOTS-Plus 14
- HIV Setting Case Definitions 16

3. Epidemiology of Tuberculosis **18**

- Epidemiological Indices 18
- Global Burden of Tuberculosis 22
- Tuberculosis Burden in India 24

4. Clinical Presentation of Tuberculosis **33**

- Congenital Tuberculosis 33
- Primary Tuberculosis 34
- Post-primary Tuberculosis 39

5. Miliary Tuberculosis **47**

- Pathogenesis 47
- Pathology 48
- Diagnosis 49
- Treatment 50
- Complications 50

6. Endobronchial Tuberculosis **52**

- Epidemiology 52
- Pathophysiology 53

- Natural History 54
- Diagnosis 55
- Differential Diagnosis 59
- Treatment 60
- Endobronchial Tuberculosis in Special Situations 61

7. Lower Lung Field Tuberculosis 69

- Definition 69
- Prevalence 70
- Pathogenesis 70
- Clinical Features 70
- Investigations 71
- Associated Medical Conditions 74
- Management 74

8. Hemoptysis 77

- Pseudo or Spurious Hemoptysis 78
- Grades of Hemoptysis 78
- Recurrent Hemoptysis 78
- Etiology of Hemoptysis 78
- Hemoptysis with Normal Chest X-ray 80
- Mechanism of Bleeding 80
- Pathogenesis of Hemoptysis in Tuberculosis 81
- Diagnosis of Hemoptysis 81
- Treatment of Hemoptysis 85

9. Diagnostic Techniques in Tuberculosis 90

9A: Diagnosis of Latent Tuberculosis Infection 90
- Tuberculin Skin Test 90
- Interferon-γ Assays 94

9B: Radiology 97
- Imaging Modalities 97
- Imaging in Pulmonary Tuberculosis 97
- Sequelae and Complications of Tuberculosis 106
- Radiographic Follow-up Schedule 107

9C: Bacteriology 109
- Direct Demonstration by Staining Technique 109
- Mycobacterial Culture in the Diagnosis of Tuberculosis 110
- Drug Susceptibility Testing 113
- Newer Tools Under Development 115

9D: Histopathology 119

9E: Polymerase Chain Reaction (PCR) 121

9F: Serology 124
- Antibody-based Tests 124
- Antigen-based Tests 128
- Serology in Diagnosing Pulmonary TB in Patients with HIV Infection 129

- Role of Serology in Diagnosing Tuberculosis in Children 130
- Role of Serology in Diagnosing Extrapulmonary TB 130

9G: Fiberoptic Bronchoscopy 134

- Indications 134
- Specimen Collected 134
- Result 135
- Precautions 136
- Drawback 136

9H: Others 138

- Fine Needle Aspiration Cytology 138
- Radioactive Bromide Particles Test 138
- Adenosine Deaminase Assay 138
- Tuberculostearic Acid Estimation 138

10. Differential Diagnosis of Pulmonary Tuberculosis 140

- Pneumonia 140
- Fungal Diseases 141
- Parasitic Disease 142
- Bronchiectasis 143
- Lung Abscess 144
- Allergic Bronchopulmonary Aspergillosis 145
- Pulmonary Edema 147
- Lung Cancer 147
- Sarcoidosis 152
- Occupational Lung Diseases 154
- Pulmonary Infarction 154
- Congenital Conditions 154
- Cardiovascular Diseases 154

11. Complications of Tuberculosis 156

- Hemoptysis 156
- Fungus Ball 157
- Bronchiectasis 159
- Tuberculosis Endobronchitis and Tracheitis 159
- Spontaneous Pneumothorax 160
- Calcification 160
- Tuberculous Laryngitis 160
- Tuberculous Enteritis 161
- Open Negative Syndrome 161
- Scar Carcinoma 162
- Physiological Changes 162
- Amyloidosis 163
- Chronic Respiratory Failure 164
- Chronic Cor Pulmonale 164

12. Post-tubercular Obstructive Airway Impairment 169
- Pathophysiology 169
- Diagnosis 171
- Treatment 172

13. Antitubercular Drugs Used in Newly Diagnosed Patients of Tuberculosis and their Adverse Effects 174
- Isoniazid 174
- Rifampicin 178
- Ethambutol 180
- Pyrazinamide 181
- Streptomycin 183
- Thioacetazone 184
- Management of Common Adverse Effect 185

14. Antitubercular Drug Used in Previously Treated Patients of Tuberculosis and their Adverse Effect 189
- Kanamycin 189
- Amikacin 194
- Capreomycin 200
- Ethionamide and Prothionamide 202
- Cycloserine 205
- Para-aminosalicylic Acid (PAS) 208
- Levofloxacin 210
- Moxifloxacin 212
- Ofloxacin 215
- Clofazimine 217
- Thiacetazone 218
- Clarithromycin 219
- Linezolid 221
- Imipenem/Cilastatin 222
- Amoxicillin Clavulanate 223

15. How Does Tuberculosis Treatment Work? 225
- Bacteriological Factors 225
- Environmental Factors 226
- Pharmacological Factors 227

16. Basic Concepts in Treatment of Tuberculosis 229
- Role of Special Diet and Rest 229
- Role of Hospitalization 230
- Single Drug Therapy versus Multiple Drugs 230
- Single versus Divided Doses 230
- Optimum Duration of Treatment 231
- Fixed Dose Combinations (FDCs) versus Separate Drugs 231

- Daily versus Intermittent Therapy 233
- Monitoring of Progress of Chemotherapy 234
- Causes of Failure of Chemotherapy 235
- Role of Surgery in Pulmonary Tuberculosis 236

17. Anti-tubercular Drug Doses and Regimens for Adults and Children 240

18. Duration of Treatment in Tuberculosis 245

- Sputum Positive Pulmonary Tuberculosis 245
- Sputum Smear-negative Pulmonary Tuberculosis 245
- Standard Conventional Long-term Nonrifampicin-containing Regimen 245

19. Treatment of Tuberculosis in Special Conditions—Pregnancy, Liver and Renal Disease 248

- Pharmacokinetics of Antitubercular Drugs 248
- Treatment of Tuberculosis in Pregnancy and Lactation 250
- Treatment of Tuberculosis in Renal Insufficiency 251
- Treatment of Tuberculosis in Liver Diseases 254

20. Treatment of Tuberculosis in Special Conditions—Pregnancy, Liver and Renal Diseases—Case-based Approach 259

- Treatment of Tuberculosis in Pregnancy and Lactation 259
- Treatment of Tuberculosis in Renal Insufficiency 260
- Treatment of Tuberculosis in Liver Disease 261

21. Treatment of Extrapulmonary Tuberculosis 263

- Tuberculous Lymphadenitis 264
- Pleural Effusion 265
- Tuberculous Meningitis (TBM) 266
- Bone and Joint Tuberculosis 267
- Miliary Tuberculosis 268
- Tuberculous Pericarditis 269
- Abdominal Tuberculosis 269
- Genitourinary Tuberculosis 270
- Ocular Tuberculosis 270
- Upper Respiratory Tract Tuberculosis 271
- Cutaneous Tuberculosis 271

22. Corticosteroids in Tuberculosis 276

- Indications of Corticosteroids in Tuberculosis 276
- Dose and Duration of Corticosteroids 281

23. Management of Retreatment Cases in Tuberculosis 284

- Relapse 284
- Defaulters or Treatment after Default 285
- Failure 286
- Poor Adherence to Treatment 286
- Drug Resistant Tuberculosis 287
- Prevention of Retreatment Cases 293

24. Drug Resistant and Multidrug Resistant Tuberculosis: Current Status 297

- Definition 297
- Types of Drug Resistance 298
- Prevalence of MDR-TB: Global 298
- Trends in MDR-TB: Global 302
- Prevalence of MDR-TB: India 303
- HIV Infection and Multidrug Resistant Tuberculosis 306
- Risk Factors of MDR-TB 308
- Sources and Causes of MDR-TB 308
- Control of MDR-TB 309

25. Drug Resistant and Multidrug Resistant Tuberculosis: Management 313

- Definition 313
- Mechanism of Drug Resistance 313
- Genetic Basis of Drug Resistance 314
- Virulence and Drug-resistant Strains 314
- Impact of Drug Resistance on the Outcome of Chemotherapy 315
- Diagnosis of Drug Resistant and Multidrug Resistant Tuberculosis 315
- Treatment of Drug Resistant and Multidrug Resistant Tuberculosis 319
- Outcome of Treatment 329

26. Multidrug Resistant Tuberculosis: Case-based Management 335

- Case I 335
- CASE II 337
- CASE III 337
- CASE IV 340
- CASE V 340
- CASE VI 343

27. Multidrug Resistant Tuberculosis—Monitoring of Treatment and Adverse Drug Reaction 345

- Pretreatment Screening and Evaluation 345
- Monitoring Progress of Treatment 345
- Monitoring for Adverse Effects During Treatment 347
- Management of Adverse Effects 348

28. Multidrug Resistant Tuberculosis—Management in Special Situation 354

- M/XDR-TB in Pregnancy 354
- M/XDR-TB in Breastfeeding 355
- M/XDR-TB in Contraception 356
- M/XDR-TB in Children 356
- M/XDR-TB in Diabetes Mellitus 358
- M/XDR-TB in Renal Insufficiency 358
- M/XDR-TB in Liver Disorders 358
- M/XDR-TB in Seizure Disorders 359
- M/XDR-TB in Substance Dependence 360
- M/XDR-TB in Patients with Psychosis 360

29. Multidrug Resistant Tuberculosis Contacts: Management 363

- Management of Symptomatic Adult 363
- Contacts of Patients with MDR-TB 363
- Management of Symptomatic Pediatric 364
- Contacts of Patients with MDR-TB 364
- Chemoprophylaxis of Contacts of DR-TB Index Cases 365

30. Multidrug Resistant and Extensively Drug Resistant Tuberculosis: Prevention 367

- General Guidelines for the Prevention of MDR- and XDR-TB 368

31. Extensively Drug Resistant Tuberculosis: Current Status and Management 374

- Definition 374
- Epidemiology 375
- Factors Responsible for XDR-TB 377
- Diagnosis 377
- Treatment 378
- Monitoring of Treatment 380
- Outcomes of Treatment 381
- Role of Surgery 382
- HIV and XDR-TB 382
- XDR-TB in Pediatric Patients 383
- XDR-TB in Pregnancy 384

- WHO Response Strategies for XDR-TB
  Control of XDR-TB 386

32. Bacillus Calmette-Guerin (BCG) 390

- Basis of Giving BCG 390
- Types of BCG Vaccine 391
- Dose and Site of Vaccination 391
- Routes of Vaccination 391
- Efficacy and Safety 391
- Contraindications to BCG Vaccination 392
- Normal Reaction after BCG Vaccination 392
- Complications 393
- Various Strategies for the Development of
  Newer Tuberculosis Vaccines 396

33. Chemoprophylaxis in Tuberculosis 402

- Chemoprophylaxis in Tuberculosis 402
- Treatment Regimens and Duration 404
- Chemoprophylaxis Under Revised National Tuberculosis
  Control Program 404
- Chemoprophylaxis for Drug Resistant Tuberculosis 405
- Limitations of Chemoprophylaxis 405
- Place of Secondary Chemoprophylaxis in
  Tuberculosis Control 405

34. Tuberculosis Control in India: DOTS 408

- Landmarks of Tuberculosis Control in India 409
- Revised National Tuberculosis Control Program Strategy 411
- Revised National Tuberculosis Control Program Structure 412
- Diagnosis Under Revised National Tuberculosis
  Control Program (RNTCP) 412
- Treatment Regimen Used in Revised National
  Tuberculosis Control Program (RNTCP) 415
- Achievements of Revised National Tuberculosis
  Control Program 420
- Others Priority Initiatives in Revised National
  Tuberculosis Control Program 421
- Impact of Revised National Tuberculosis Control Program 424
- Challenges for Revised National Tuberculosis
  Control Program 424
- Problems of Revised National Tuberculosis
  Control Program 425

35. Tuberculosis Control in India: DOTS Plus 427

- Framework 427
- Case Finding Strategy 428

- Enrolment into DOTS-Plus Program 429
- Confirmed MDR-TB Case 430
- Drug Resistant Tuberculosis Center 431
- Pre-treatment Evaluation 432
- Counseling 432
- Monitoring Progress During Treatment 433
- Category IV Regimen 434
- Drug Dosages and Administration 434
- Treatment Duration 435
- Regimen for XDR-TB 436
- Duration of Regimen for XDR-TB 436
- Treatment Interruption and Default 437
- Treatment Outcomes 438
- Providing Patient and Family Counseling 439
- Monitoring for Early Detection of Adverse Reactions 440
- Role of DR-TB Committee in the 440
- Management of Adverse Reactions 440
- Adherence 441
- Follow-up of the Non-adherent Patient 441
- DOTS-Plus Plan 442

36. Tuberculosis and HIV 444

- Epidemiology 444
- Impact of HIV on Tuberculosis 445
- Impact of Tuberculosis on HIV 446
- Diagnostic Difficulties in Persons with HIV/TB 446
- Coinfection 446
- Revised WHO Clinical Staging of HIV/AIDS for Adults and Adolescents with Confirmed HIV Infection 446
- Diagnosis of Pulmonary Tuberculosis 448
- Extrapulmonary Tuberculosis 450
- Investigations 452
- Treatment of Tuberculosis in HIV Positive Patients 454
- Adjuvant Corticosteroids in Extrapulmonary TB 455
- Highly Active Antiretroviral Therapy 455
- Interactions of Antituberculosis 456
- Therapy and Antiretroviral Therapy 456
- Immune Reconstitution Syndrome 458
- HIV and Drug Resistant TB Drug Interactions of Second Line Drugs and ART 459
- Recurrence of Tuberculosis after Completion of Tuberculosis Treatment 460
- Treatment of TB and HIV—WHO Recommended Collaborative TB/HIV Activities 460

37. Interaction between Antitubercular and Antiretroviral Drugs 465

- Antiretroviral Therapy for the Treatment of HIV Infection 465
- Pharmacokinetic Issues in the Treatment of HIV-related Tuberculosis 469
- Interaction between Antiretroviral and Antitubercular Drugs 469
- Drug-Drug Interactions in the Treatment of HIV and Drug Resistant-TB (DR-TB) 471

38. Tuberculosis and Diabetes 473

- Epidemiology 473
- Effect of Diabetes on Pulmonary Tuberculosis 474
- Effect of Pulmonary Tuberculosis on Diabetes 475
- Clinical Features and Course of Tuberculosis in Diabetics 475
- Roentgenographic Aspects of Tuberculosis in Diabetics 476
- Multidrug Resistant Tuberculosis (MDR-TB) and Diabetes 477
- Effect of Antituberculosis Drugs on Blood 477
- Glucose Level and OHA in Tubercular Diabetics 477
- Principles of Management 477

39. Tuberculosis and Pregnancy 480

- Effect of Pregnancy on Tuberculosis 480
- Effect of Tuberculosis on Pregnancy and Childbirth 481
- Diagnosis of Tuberculosis in Pregnant Woman 481
- Treatment of Pregnant Woman with Active Tuberculosis 482
- Treatment of Tuberculosis in Lactating Woman 483
- Isoniazid Prophylaxis in Pregnant Woman 484
- Isoniazid Prophylaxis for Infant Born to Woman with Active Tuberculosis 484

40. Tubercular Pleural Effusion 487

- Epidemiology 487
- Pathogenesis 487
- Clinical Manifestations 488
- Clinical Manifestations in HIV Positive Patients 489
- Diagnosis 489
- Natural History of Untreated Tuberculous Effusion 496
- Treatment 496
- Response to Treatment 498

41. Tubercular Empyema 504

- Etiopathogenesis 504
- Clinical Features 505

- Diagnosis 506
- Treatment 506

42. Tubercular Lymphadenitis 511

- Epidemiology 511
- Pathogenesis 512
- Clinical Features 512
- Diagnosis 513
- Treatment 515

43. Tuberculosis in Children 518

- Epidemiology 518
- Clinical Presentation of Tuberculosis 520
- Postprimary Extrapulmonary Tuberculosis 520
- Diagnosis of Childhood Tuberculosis 520
- Treatment of Tuberculosis in Children 522

44. Tuberculosis in Elderly 527

- Epidemiology 527
- Reasons for Reactivation 528
- Clinical Features 528
- Diagnosis 530
- Investigations in Tuberculosis in Elderly 530
- Treatment 531

45. Tuberculosis Abdomen 533

- Pathogenesis 533
- Clinical Features 534
- Investigations 538
- Treatment of Abdominal Tuberculosis 543

46. Tuberculosis of Kidney and Urinary Tract 547

- Epidemiology 547
- Pathophysiology 548
- Clinical Features 548
- Diagnosis of Tuberculosis of Kidney and Urinary Tract 551
- Treatment 556

47. Genitourinary Tuberculosis in Male 559

- Epidemiology 559
- Pathogenesis 559
- Clinical Features 560
- Investigations 561
- Treatment 563

48. Genitourinary Tuberculosis in Female 566

- Epidimiology 566

- Pathogenesis 567
- Clinical Presentation of Female Genital Tuberculoisis 568
- Diagnosis 568
- Treatment 571

49. Non-tubercular Mycobacteria 573

- Epidemiology 573
- Mode of Infections 574
- Classifications of NTM 575
- Distribution 576
- Clinical Presentations 576
- Diagnosis 577
- Features of NTM 580
- Treatment 582

50. Infection Control in Tuberculosis 587

- Mode of Infection in Tuberculosis 587
- The Difference between TB Infection and TB Disease 588
- Standard Precautions 589
- Hierarchy of Infection Control to Reduce Risk of Transmission of Respiratory Pathogens 589
- Managerial Activities for National, State, Hospital Administration, and Local Health Officials 590
- Administrative Control Strategies for Healthcare Facilities 591
- Environmental Control Measures 594
- Protection of Healthcare Workers and Staff 595
- Multidrug Resistant TB 596
- Drug Rehabilitation Centers and Corelations Institutions 597

Index 599